204 related articles for article (PubMed ID: 30971156)
21. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis.
Han T; Yang X; Zhang Y; Li G; Liu L; Chen T; Zheng Z
Biosci Trends; 2019 Nov; 13(5):374-381. PubMed ID: 31611486
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
23. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.
Han S; Zhang X; Zou L; Lu C; Zhang J; Li J; Li M
PLoS One; 2014; 9(8):e102686. PubMed ID: 25083860
[TBL] [Abstract][Full Text] [Related]
24. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
25. Bile Duct Injury after Transcatheter Arterial Chemoembolization: Risk Factors and Clinical Implications.
Wang Z; Wang M; Duan F; Song P; Liu F
Hepatogastroenterology; 2014 Jun; 61(132):947-53. PubMed ID: 26158147
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary embolism after transcatheter arterial chemoembolization.
Shiah HS; Liu TW; Chen LT; Chang JY; Liu JM; Chuang TR; Lee WS; Whang-Peng J
Eur J Cancer Care (Engl); 2005 Dec; 14(5):440-2. PubMed ID: 16274465
[TBL] [Abstract][Full Text] [Related]
27. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
29. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
[TBL] [Abstract][Full Text] [Related]
31. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.
Vogl TJ; Lammer J; Lencioni R; Malagari K; Watkinson A; Pilleul F; Denys A; Lee C
AJR Am J Roentgenol; 2011 Oct; 197(4):W562-70. PubMed ID: 21940527
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
33. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
34. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
[TBL] [Abstract][Full Text] [Related]
35. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
[TBL] [Abstract][Full Text] [Related]
36. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.
Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R
Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056
[TBL] [Abstract][Full Text] [Related]
39. Risk factors of liver abscess and biloma formation after drug-eluting bead transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma.
Bian L; Yang J; Song Z
Arab J Gastroenterol; 2024 May; 25(2):176-181. PubMed ID: 38388217
[TBL] [Abstract][Full Text] [Related]
40. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]